These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 28875336

  • 1. Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT).
    Maira D, Cassinerio E, Marcon A, Mancarella M, Fraquelli M, Pedrotti P, Cappellini MD.
    Ann Hematol; 2017 Nov; 96(11):1931-1936. PubMed ID: 28875336
    [Abstract] [Full Text] [Related]

  • 2. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
    Elalfy MS, Esmat G, Matter RM, Abdel Aziz HE, Massoud WA.
    Ann Hepatol; 2013 Nov; 12(1):54-61. PubMed ID: 23293194
    [Abstract] [Full Text] [Related]

  • 3. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
    Karakas Z, Yilmaz Y, Bayramoglu Z, Karaman S, Aydogdu S, Karagenc AO, Tugcu D, Dursun M.
    Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Aug; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 8. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK.
    Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
    Elalfy MS, Adly A, Awad H, Tarif Salam M, Berdoukas V, Tricta F.
    Am J Hematol; 2018 Feb 13; 93(2):262-268. PubMed ID: 29119631
    [Abstract] [Full Text] [Related]

  • 13. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y.
    Hematol Oncol Clin North Am; 2018 Apr 13; 32(2):261-275. PubMed ID: 29458731
    [Abstract] [Full Text] [Related]

  • 14. Cardiac T2* MR in patients with thalassemia major: a 10-year long-term follow-up.
    Daar S, Al Khabori M, Al Rahbi S, Hassan M, El Tigani A, Pennell DJ.
    Ann Hematol; 2020 Sep 13; 99(9):2009-2017. PubMed ID: 32556452
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Sep 13; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 16. Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study.
    Bayraktaroglu S, Karadas N, Onen S, Karapinar DY, Aydinok Y.
    Ann Hematol; 2022 Mar 13; 101(3):521-529. PubMed ID: 34985558
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
    Gupta V, Kumar I, Raj V, Aggarwal P, Agrawal V.
    Pediatr Blood Cancer; 2022 Jun 13; 69(6):e29564. PubMed ID: 35092347
    [Abstract] [Full Text] [Related]

  • 18. Reduction of cardiac iron overload by optimising iron chelation therapy in transfusion dependent thalassaemia using cardiac T2* MRI: a quality improvement project from Pakistan.
    Hussain S, Hoodbhoy Z, Ali F, Hasan E, Alvi N, Hussain A, Ishrat K, Ur Rahman Z, Qamruddin A, Parvin A, Hasan BS.
    Arch Dis Child; 2020 Nov 13; 105(11):1041-1048. PubMed ID: 32994214
    [Abstract] [Full Text] [Related]

  • 19. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 13; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 20. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct 13; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.